Sanofi-a Ventis Deutschland Gmbh

Aventis Pharma Deutschland, Gmbh

Mark Brönstrup

Cordula Hopmann

Joachim Wink

Michael Kurz

Luigi Toti

Martin Knauf

Astrid Markus-Erb

The present invention relates to novel hydroxyphenylundecane derivatives of the formula (I), a method for the preparation of said compounds by cultivation of the fungus, DSM 14453, and their use as pharmaceuticals, i.e. for the treatment of Alzheimer's Disease, Parkinson's Disease, Huntington's Diseases, stroke, psychosis and/or depressions.

Hydroxyphenylundecane, a process for their production and their use

The present invention relates to novel active compounds named Citrullimycines, which are obtainable by cultivation ofsp. ST 101396 (DSM 13309), and to their pharmaceutically acceptable salts and derivatives. The present invention further relates to a process for the production of the Citrullimycines, to the microorganismsp. ST 101396 (DSM 13309), to the use of the Citrullimycines and their pharmaceutically acceptable salts and derivatives as pharmaceuticals, for example as inhibitors of the neurotensin receptor, and to pharmaceutical compositions comprising Citrullimycines or a pharmaceutically acceptable salt or derivative thereof.

Citrullimycines, a process for their production and their use as pharmaceuticals

Growing community of inventors

Frankfurt-am-Main, Germany

Mark Brönstrup